Phase 3 Head and Neck Cancer Trial, Recruiting NCT05547529 Sponsor: Blokhin's Russian Cancer Research Center Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT05547529
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given written consent to participate.
  • People who have been diagnosed with squamous cell carcinoma (a specific type of cancer) of the oesophagus (food pipe), confirmed by a tissue sample.
  • People whose cancer has been staged as cT1-4aN1-3M0, meaning the cancer has spread to nearby lymph nodes but not to distant parts of the body (confirm with trial site for exact staging details).
  • People whose cancer has been assessed as needing surgical removal of the oesophagus.
  • People who are fully active or have only minor restrictions in physical activity (ECOG performance score of 0 or 1).
  • People whose blood counts are within acceptable ranges, indicating the bone marrow is working well enough.
  • People whose liver function test results are within acceptable ranges.
  • People whose kidneys are filtering blood at an adequate rate.
  • People whose heart is pumping blood effectively, with a heart pumping function above 50%.
  • People aged between 18 and 70 years old.

Who may not be able to join:

  • People whose cancer has been staged as cT4bcN0cM0, meaning the tumour has grown into nearby structures in a way that makes surgery unlikely (confirm with trial site).
  • People whose oesophageal cancer is advanced, inoperable, or has spread to distant parts of the body.
  • People who have already received or are currently receiving chemotherapy, radiotherapy, or targeted cancer therapy.
  • People who have had or currently have another cancer diagnosis.
  • People with known allergies or medical reasons preventing the use of any of the chemotherapy drugs used in this trial (Paclitaxel, Carboplatin, Docetaxel, Cisplatin, or Fluorouracil).
  • People with an active HIV, Hepatitis B, or Hepatitis C infection, or who test positive for these viruses.
  • People with serious ongoing health conditions that are not well controlled, such as high blood pressure, diabetes, a stroke within the last 6 months, or mental health disorders.
  • People with significant heart disease, heart failure, serious heart muscle disease, a heart attack within the last 6 months, or a high risk of dangerous irregular heart rhythms.
  • People with chronic inflammatory conditions of the digestive tract.
  • People with a current acute (sudden and active) infectious illness.
  • People who are pregnant or breastfeeding.
  • People with serious physical or mental health conditions, or other circumstances, that may prevent them from following the trial schedule and requirements.
  • People who are foreign nationals or who have restricted legal rights (confirm with trial site for clarification on this criterion).
  • People where the trial investigator considers any medical, geographic, or social circumstance makes participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +79269125902

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Blokhin's Russian Cancer Research Center
Registry
ClinicalTrials.gov
Start date
14 September 2022
Est. completion
14 September 2025

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov